Lv4
510 积分 2025-07-02 加入
Approaches to Improve the Translation of Safety, Pharmacokinetics and Therapeutic Index of ADCs
18天前
已完结
The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer
24天前
已完结
Use of pharmacokinetic versus pharmacodynamic endpoints to support human dose predictions: implications for rational drug design and early clinical development
30天前
已完结
Unlocking the potential of antibody–drug conjugates for cancer therapy
1个月前
已完结
Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicities
1个月前
已完结
Pharmacokinetics and Toxicity Considerations for Antibody–drug Conjugates: An Overview
1个月前
已完结
Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates
1个月前
已完结
Meta‐Analysis of Exposure‐Adverse Event Relationships for Antibody–Drug Conjugates
1个月前
已完结
Toxicities From Antibody-Drug Conjugates
1个月前
已完结
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
1个月前
已完结
皖公网安备34019202002308
